Canaan Partners
VC Fund
Menlo Park, United States
Canaan Partners is a VC fund in Menlo Park focused on Software and Biotechnology. Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.
- Total investments:
- 772
- Last investment:
- Lead investor:
- 32%
- Fund size:
- $100M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Canaan Partners invests in
Stages Canaan Partners invests in
Countries Canaan Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 20 contacts → | |||
Round size
- Series A
- $5.5M–$45M
- Series B
- $8M–$75M
- Series C
- $8M–$60M
Investment Focus
Industry
- Software 79 (10%)
- Biotechnology 76 (10%)
- Health Care 71 (9%)
- Medical 40 (5%)
- Enterprise Software 32 (4%)
Stage
- Series A 143 (19%)
- Series B 142 (18%)
- Series C 87 (11%)
- Seed 70 (9%)
- Funding Round 51 (7%)
Country
- United States 285 (37%)
- United Kingdom 10 (1%)
- Israel 9 (1%)
- India 7 (1%)
- Brazil 4 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Deepak Kamra
General Partner
|
General Partner | Total investments: 41 | Find email | |
Peter Farina
Executive in Residence
|
Executive in Residence | Total investments: 2 | Find email | |
Bob Williams
VC In Residence
|
VC In Residence | Total investments: 7 | Find email | |
Brendan Dickinson
General Partner
|
General Partner | Total investments: 25 | Find email | |
Brenton Ahrens
General Partner
|
General Partner | Total investments: 35 | Find email | |
| See all 20 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Solstice Oncology
|
Solstice Oncology is a clinical stage immuno-oncology company developing a therapeutic that meets cancer at its most vulnerable moment, before surgery, to drive deep pathological response and return patients to lasting health. The company's lead program is targeting colon cancer. | $225M / Series A / Sep 09, 2026 | |
Actualyze AI
|
ActualyzeAI is a company focused on helping enterprises manage and gain control over AI adoption. It provides tools for visibility, governance, and oversight so organizations can scale AI usage without reducing team productivity. | $7M / Seed / Aug 03, 2026 | |
Mate
|
Mate provides an AI-powered SOC solution that learns from an organization’s best analysts and builds a contextual data. | $35M / Series A / Jul 28, 2026 | |
Vedana Therapeutics
|
Vedana Therapeutics is a Seattle biotechnology company developing next-generation antibody therapies for migraine prevention. | $46M / Series A / Jun 17, 2026 | |
AttoTude
|
AttoTude develops interconnect technology for artificial intelligence and hyperscale data center environments. The company designs terahertz (THz) communication solutions that enable high-speed data transfer between computing systems and network components. Its technology focuses on addressing bandwidth, power consumption, scalability, andconnectivity challenges associated with large-scale AI processing and data-intensive workloads. | $52M / Series C / Jun 15, 2026 | |
Rylo
|
Nagish stands for 'Accessible' in Hebrew and our mission is to make phone calls more accessible. We believe that everyone should have the right to use a phone without having someone listening to their private calls. Nagish gives its users full ownership of their calls by converting text-to-speech and speech-to-text in real-time so thatone side of a phone call could type and read while the other side can hear and speak. | $85M / Venture - Series Unknown / Jun 09, 2026 | |
SageOx
|
SageOx develops context infrastructure that keeps humans and AI agents aligned around shared decisions and knowledge. The platform captures discussions, coding sessions, and assistant chats, then converts them into structured, searchable team memory. SageOx injects this context into AI coding agents and assistants at the start of each session sothey can follow team conventions and prior decisions. Its Ox Dot device records in‑room conversations, while the Ox CLI connects repositories and agent workflows to shared context. Ox MCP links ChatGPT, Claude, and other MCP-compatible assistants to the same memory, and Ox Console gives teams a unified view across decisions, sessions, and recordings. | $15M / Seed / May 06, 2026 | |
Treasury
|
Treasury is an investing education platform for the Her First $100K community that combines non-judgmental and jargon-free videos & articles | $2.5M / Seed / May 06, 2026 | |
C-Infinity
|
C-Infinity develops artificial intelligence software and services for data processing, automation, and decision support. building foundational AI for mechanical design and manufacturing—AI that reasons about geometry, motion, constraints, and production logic. | $16M / Seed / Apr 22, 2026 | |
Hermeus
|
Hermeus is an aerospace and defense company that develops hypersonic aircraft capable of reaching speeds around Mach 5. The company’s core mission is to drastically reduce global travel times by creating next-generation aircraft that can fly significantly faster than traditional commercial jets. Its flagship programs include the Quarterhorse seriesof high-speed test aircraft and the development of the Chimera engine, a turbine-based combined cycle propulsion system designed for hypersonic flight. Hermeus follows a rapid, iterative development approach, building and testing multiple prototypes to accelerate innovation and reduce engineering timelines. The company collaborates with organizations such as the U.S. Air Force and NASA, positioning its technology for both commercial aviation and defense applications. | $200M / Series C / Apr 07, 2026 | |
| See all 772 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Canaan Partners invest in?
Canaan Partners invests primarily in Software, Biotechnology and Health Care startups, most often at Series A and Series B stage. Most of the 772 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Canaan Partners's check size?
Canaan Partners typically joins rounds of $5.5M–$45M at Series A, $8M–$75M at Series B and $8M–$60M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Canaan Partners participates in.
How do I contact Canaan Partners?
Public channels for Canaan Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Canaan Partners?
The team at Canaan Partners includes Deepak Kamra (General Partner), Peter Farina (Executive in Residence) and Bob Williams (VC In Residence), among 20 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
